Interaction between two HTR2A polymorphisms and gender is associated with treatment response in MDD

Neuroscience Letters

Volumn 501, Issue 1, 2011, Pages 20-24

  Viikki, Merja ^a,b   Huuhka, Kaija ^c   Leinonen, Esa ^a,c   Illi, Ari ^a,d   Setälä Soikkeli, Eija ^e   Huuhka, Martti ^c   Mononen, Nina ^c   Lehtimäki, Terho ^c   Kampman, Olli ^a,f  

^a TAMPERE UNIVERSITY OF TECHNOLOGY   (Finland)

^b Tampere Mental Health Centre   (Finland)

^c TAMPERE UNIVERSITY HOSPITAL   (Finland)

^d Satakunta Hospital District   (Finland)

^e KANTA HÄME CENTRAL HOSPITAL   (Finland)

^f SEINÄJOKI CENTRAL HOSPITAL   (Finland)

Author keywords

102T C; 1438A G; 5HT2A; ECT; Gene polymorphism; MADRS score change; Mood disorders; Pharmacogenetics; Rs6311; Rs7997012; Treatment resistant depression

Indexed keywords

CITALOPRAM; FLUOXETINE; PAROXETINE; SEROTONIN RECEPTOR;

ARTICLE; CORRELATIONAL STUDY; FEMALE; GENDER; GENOTYPE; HUMAN; MAJOR CLINICAL STUDY; MAJOR DEPRESSION; MALE; MONTGOMERY ASBERG DEPRESSION RATING SCALE; OUTPATIENT CARE; PRIORITY JOURNAL; REMISSION; SINGLE NUCLEOTIDE POLYMORPHISM; TREATMENT RESPONSE;

ADULT; ALLELES; DEPRESSIVE DISORDER, MAJOR; ELECTROCONVULSIVE THERAPY; FEMALE; GENETIC ASSOCIATION STUDIES; GENOTYPE; HUMANS; MALE; POLYMORPHISM, SINGLE NUCLEOTIDE; RECEPTOR, SEROTONIN, 5-HT2A; SEROTONIN UPTAKE INHIBITORS; SEX FACTORS; TREATMENT OUTCOME;

EID: 79961001198     PISSN: 03043940     EISSN: 18727972     Source Type: Journal    
DOI: 10.1016/j.neulet.2011.06.031     Document Type: Article

References (36)

1. Anttila S., Huuhka K., Huuhka M., Rontu R., Mattila K.M., Leinonen E., Lehtimäki T. Interaction between TPH1 and GNB3 genotypes and electroconvulsive therapy in major depression. J. Neural. Transm. 2007, 114:461-468.
2. Bortolozzi A., Díaz-Mataix L., Scorza M.C., Celada P., Artigas F. The activation of 5-HT receptors in prefrontal cortex enhances dopaminergic activity. J. Neurochem. 2005, 95:1597-1607.
3. Burnet P.W., Eastwood S.L., Lacey K., Harrison P.J. The distribution of 5-HT1A and 5-HT2A receptor mRNA in human brain. Brain Res. 1995, 676:157-168.
4. Cassidy F., Murry E., Weiner R.D., Carroll B.J. Lack of relapse with tryptophan depletion following successful treatment with ECT. Am. J. Psychiatry 1997, 154:1151-1152.
5. Cassidy F., Weiner R.D., Cooper T.B., Carroll B.J. Combined catecholamine and indoleamine depletion following response to ECT. Br. J. Psychiatry 2010, 196:493-494.
6. Chen K., Yang W., Grimsby J., Shih J.C. The human 5-HT2 receptor is encoded by a multiple intron-exon gene. Brain Res. Mol. Brain Res. 1992, 14:20-26.
7. Choi M.J., Kang R.H., Ham B.J., Jeong H.Y., Lee M.S. Serotonin receptor 2A gene polymorphism (-1438A/G) and short-term treatment response to citalopram. Neuropsychobiology 2005, 52:155-162.
8. Cusin C., Serretti A., Zanardi R., Lattuada E., Rossini D., Lilli R., Lorenzi C., Smeraldi E. Influence of monoamine oxidase A and serotonin receptor 2A polymorphisms in SSRI antidepressant activity. Int. J. Neuropsychopharmacol. 2002, 5:27-35.
9. Hong C.J., Chen T.J., Yu Y.W., Tsai S.J. Response to fluoxetine and serotonin 1A receptor (C-1019G) polymorphism in Taiwan Chinese major depressive disorder. Pharmacogenomics J. 2006, 6:27-33.
10. Horstmann S., Lucae S., Menke A., Hennings J.M., Ising M., Roeske D., Müller-Myhsok B., Holsboer F., Binder E.B. Polymorphisms in GRIK4, HTR2A, and FKBP5 show interactive effects in predicting MADRS score change to antidepressant treatment. Neuropsychopharmacology 2010, 35:727-740.
11. Huezo-Diaz P., Uher R., Smith R., Rietschel M., Henigsberg N., Marusic A., Mors O., Maier W., Hauser J., Souery D., Placentino A., Zobel A., Larsen E.R., Czerski P.M., Gupta B., Hoda F., Perroud N., Farmer A., Craig I., Aitchison K.J., McGuffin P. Moderation of antidepressant response by the serotonin transporter gene. Br. J. Psychiatry 2009, 195:30-38.
12. Illi A., Setälä-Soikkeli E., Viikki M., Poutanen O., Huhtala H., Mononen N., Lehtimäki T., Leinonen E., Kampman O. 5-HTR1A, 5-HTR2A, 5-HTR6, TPH1 and TPH2 polymorphisms and major depression. Neuroreport 2009, 20:1125-1128.
13. Kang R.H., Choi M.J., Paik J.W., Hahn S.W., Lee M.S. Effect of serotonin receptor 2A gene polymorphism on mirtazapine response in major depression. Int. J. Psychiatry Med. 2007, 37:315-329.
14. Kato M., Fukuda T., Wakeno M., Fukuda K., Okugawa G., Ikenaga Y., Yamashita M., Takekita Y., Nobuhara K., Azuma J., Kinoshita T. Effects of the serotonin type 2A, 3A and 3B receptor and the serotonin transporter genes on paroxetine and fluvoxamine efficacy and adverse drug reactions in depressed Japanese patients. Neuropsychobiology 2006, 53:186-195.
15. Kato M., Zanardi R., Rossini D., De Ronchi D., Okugawa G., Kinoshita T., Colombo C., Serretti A. 5-HT2A gene variants influence specific and different aspects of antidepressant response in Japanese and Italian mood disorder patients. Psychiatry Res. 2009, 167:97-105.
16. Kato M., Serretti A. Review and meta-analysis of antidepressant pharmacogenetic findings in major depressive disorder. Mol. Psychiatry 2010, 15:473-500.
17. Keers R., Aitchison K.J. Gender differences in antidepressant drug response. Int. Rev. Psychiatry 2010, 22:485-500.
18. Kornstein S.G., Schatzberg A.F., Thase M.E., Yonkers K.A., McCullough J.P., Keitner G.I., Gelenberg A.J., Davis S.M., Harrison W.M., Keller M.B. Gender differences in treatment response to sertraline versus imipramine in chronic depression. Am. J. Psychiatry 2000, 157:1445-1452.
19. Landen M., Thase M.E. A model to explain the therapeutic effects of serotonin reuptake inhibitors: the role of 5-HT2 receptors. Psychopharmacol. Bull. 2006, 39:147-166.
20. McMahon F.J., Buervenich S., Charney D., Lipsky R., Rush A.J., Wilson A.F., Sorant A.J., Papanicolaou G.J., Laje G., Fava M., Trivedi M.H., Wisniewski S.R., Manji H. Variation in the gene encoding the serotonin 2A receptor is associated with outcome of antidepressant treatment. Am. J. Hum. Genet. 2006, 78:804-814.
21. Minov C., Baghai T.C., Schüle C., Zwanzger P., Schwarz M.J., Zill P., Rupprecht R., Bondy B. Serotonin-2A-receptor and -transporter polymorphisms: lack of association in patients with major depression. Neurosci. Lett. 2001, 303:119-122.
22. Montgomery S.A., Åsberg M. A new depression scale designed to be sensitive to change. Br. J. Psychiatry 1979, 134:382-389.
23. Myers R.L., Airey D.C., Manier D.H., Shelton R.C., Sanders-Bush E. Polymorphisms in the regulatory region of the human serotonin 5-HT2A receptor gene (HTR2A) influence gene expression. Biol. Psychiatry 2007, 61:167-173.
24. Noro M., Antonijevic I., Forray C., Kasper S., Kocabas N.A., Lecrubier Y., Linotte S., Mendlewicz J., Montgomery S., Snyder L., Souery D., Verbanck P., Zohar J., Massat I. 5HT1A and 5HT2A receptor genes in treatment response phenotypes in major depressive disorder. Int. Clin. Psychopharmacol. 2010, 25:228-231.
25. Paddock S., Laje G., Charney D., Rush A.J., Wilson A.F., Sorant A.J., Lipsky R., Wisniewski S.R., Manji H., McMahon F.J. Association of GRIK4 with outcome of antidepressant treatment in the STAR*D cohort. Am. J. Psychiatry 2007, 164:1181-1188.
26. Parker G., Parker K., Austin M.P., Mitchell P., Brotchie H. Gender differences in response to differing antidepressant drug classes: two negative studies. Psychol. Med. 2003, 33:1473-1477.
27. Parsons M.J., D'Souza U.M., Arranz M.J., Kerwin R.W., Makoff A.J. The -1438A/G polymorphism in the 5-hydroxytryptamine type 2A receptor gene affects promoter activity. Biol. Psychiatry 2004, 56:406-410.
28. Peters E.J., Slager S.L., McGrath P.J., Knowles J.A., Hamilton S.P. Investigation of serotonin-related genes in antidepressant response. Mol. Psychiatry 2004, 9:879-889.
29. Sato K., Yoshida K., Takahashi H., Ito K., Kamata M., Higuchi H., Shimizu T., Itoh K., Inoue K., Tezuka T., Suzuki T., Ohkubo T., Sugawara K., Otani K. Association between -1438G/A promoter polymorphism in the 5-HT(2A) receptor gene and fluvoxamine response in Japanese patients with major depressive disorder. Neuropsychobiology 2002, 46:136-140.
30. Sparkes R.S., Lan N., Klisak I., Mohandas T., Diep A., Kojis T., Heinzmann C., Shih J.C. Assignment of a serotonin 5HT-2 receptor gene (HTR2) to human chromosome 13q14-q21 and mouse chromosome 14. Genomics 1991, 9:461-465.
31. Spurlock G., Heils A., Holmans P., Williams J., D'Souza U.M., Cardno A., Murphy K.C., Jones L., Buckland P.R., McGuffin P., Lesch K.P., Owen M.J. A family based association study of T102C polymorphism in 5HT2A and schizophrenia plus identification of new polymorphisms in the promoter. Mol. Psychiatry 1998, 3:42-49.
32. Trivedi M.H., Rush A.J., Wisniewski S.R., Nierenberg A.A., Warden D., Ritz L., Norquist G., Howland R.H., Lebowitz B., McGrath P.J., Shores-Wilson K., Biggs M.M., Balasubramani G.K., Fava M., STAR*D Study Team Evaluation of outcomes with citalopram for depression using measurement-based care in STAR*D: implications for clinical practice. Am. J. Psychiatry 2006, 163:28-40.
33. Uher R., Huezo-Diaz P., Perroud N., Smith R., Rietschel M., Mors O., Hauser J., Maier W., Kozel D., Henigsberg N., Barreto M., Placentino A., Dernovsek M.Z., Schulze T.G., Kalember P., Zobel A., Czerski P.M., Larsen E.R., Souery D., Giovannini C., Gray J.M., Lewis C.M., Farmer A., Aitchison K.J., McGuffin P., Craig I. Genetic predictors of response to antidepressants in the GENDEP project. Pharmacogenomics J. 2009, 9:225-233.
34. Viikki M., Anttila S., Kampman O., Illi A., Huuhka M., Setälä-Soikkeli E., Mononen N., Lehtimäki T., Leinonen E. Vascular endothelial growth factor (VEGF) polymorphism is associated with treatment resistant depression. Neurosci. Lett. 2010, 47:105-108.
35. Yatham L.N., Liddle P.F., Lam R.W., Zis A.P., Stoessl A.J., Sossi V., Adam M.J., Ruth T.J. Effect of electroconvulsive therapy on brain 5-HT(2) receptors in major depression. Br. J. Psychiatry 2010, 196:474-479.
36. Young E., Korszun A. Sex, trauma, stress hormones and depression. Mol. Psychiatry 2010, 15:23-28.